Design and optimisation of Photochrome Aptamer Switch Assay (PHASA)

Zhou, Yubin; Wu, Yuanyuan; Pokholenko, Oleksandr; Papper, Vladislav; Marks, Robert S.; Steele, Terry W. J.

doi:10.1016/j.aca.2019.01.049

Cited by 7 publications

(2 citation statements)

References 25 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides these advantages, aptamers are able to change conformation upon adaptive binding with their targets, providing a basis to induce fluorescent signaling/quenching events. 238,[254][255][256][257] Sosic et al 243 developed a multiplex sandwich aptamer microarray (SAM) for the simultaneous detection of VEGF 165 and thrombin. In this system, the modified aptamers Vap7(12T)NH 2 and the 15-mer TBA1(12T)NH 2 were anchored on distinct spots on a microarray slide as capture layer for VEGF 165 and thrombin respectively, while…”

Section: Fluorescence-based Vegf Aptasensors and Nano-aptasensorsmentioning

confidence: 99%

“…Fluorescence is the emission of light arising from direct photoexcitation of the emitting species 253 and is one of the most exploited techniques in the construction of highly selective biosensors, because of its rapidity of detection, high sensitivity and favorable cost‐effectiveness ratios. Besides these advantages, aptamers are able to change conformation upon adaptive binding with their targets, providing a basis to induce fluorescent signaling/quenching events 238,254–257 …”

Section: Dna‐based Aptasensors For Vegf Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics

Riccardi

Napolitano

Platella

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

The vascular endothelial growth factor (VEGF) family and its receptors play fundamental roles not only in physiological but also in pathological angiogenesis, characteristic of cancer progression. Aiming at finding putative treatments for several malignancies, various small molecules, antibodies, or protein‐based drugs have been evaluated in vitro and in vivo as VEGF inhibitors, providing efficient agents approved for clinical use. Due to the high clinical importance of VEGF, also a great number of anti‐VEGF nucleic acid‐based aptamers—that is, oligonucleotides able to bind with high affinity and specificity a selected biological target—have been developed as promising agents in anticancer strategies. Notable research efforts have been made in optimization processes of the identified aptamers, searching for increased target affinity and/or bioactivity by exploring structural analogues of the lead compounds. This review is focused on recent studies devoted to the development of DNA‐based aptamers designed to target VEGF. Their therapeutic potential as well as their significance in the construction of highly selective biosensors is here discussed.

show abstract